Application of iron oxide nanoparticles to control the release of minocycline for the treatment of glioblastoma
Background: The utilization of iron oxide nanoparticles (Fe3O4 NPs) to control minocycline release rates from poly(lactic-co-glycolic acid) scaffolds fabricated from an easy/economical technique is presented. Results & methodology: A larger change in temperature and amount of minocycline released was observed for scaffolds with higher amounts of Fe3O4 NPs, demonstrating that nanoparticle concentration can control heat generation and minocycline release. Temperatures near a polymer's glass transition temperature can result in the polymer's chain becoming more mobile and thus increasing drug diffusion out of the scaffold. Elevated temperature and minocycline released from the scaffold can work synergistically to enhance glioblastoma cell death. Conclusion: This study suggests that Fe3O4 NPs are promising materials for controlling minocycline release from polymeric scaffolds by magnetic hyperthermia for the treatment of glioblastoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 13(2021), 21 vom: 13. Nov., Seite 1833-1843 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arriaga, Marco A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.02.2022 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2021-0098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330875973 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330875973 | ||
| 003 | DE-627 | ||
| 005 | 20240403233631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2021-0098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM330875973 | ||
| 035 | |a (NLM)34545754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arriaga, Marco A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of iron oxide nanoparticles to control the release of minocycline for the treatment of glioblastoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2022 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The utilization of iron oxide nanoparticles (Fe3O4 NPs) to control minocycline release rates from poly(lactic-co-glycolic acid) scaffolds fabricated from an easy/economical technique is presented. Results & methodology: A larger change in temperature and amount of minocycline released was observed for scaffolds with higher amounts of Fe3O4 NPs, demonstrating that nanoparticle concentration can control heat generation and minocycline release. Temperatures near a polymer's glass transition temperature can result in the polymer's chain becoming more mobile and thus increasing drug diffusion out of the scaffold. Elevated temperature and minocycline released from the scaffold can work synergistically to enhance glioblastoma cell death. Conclusion: This study suggests that Fe3O4 NPs are promising materials for controlling minocycline release from polymeric scaffolds by magnetic hyperthermia for the treatment of glioblastoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a PLGA scaffolds | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a hyperthermia | |
| 650 | 4 | |a iron oxide nanoparticles | |
| 650 | 4 | |a minocycline | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Minocycline |2 NLM | |
| 650 | 7 | |a FYY3R43WGO |2 NLM | |
| 700 | 1 | |a Enriquez, Dean Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Salinas, Arely D |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Romeo |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Trevino De Leo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Silverio A |e verfasserin |4 aut | |
| 700 | 1 | |a Martirosyan, Karen S |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Sue Anne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 13(2021), 21 vom: 13. Nov., Seite 1833-1843 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:21 |g day:13 |g month:11 |g pages:1833-1843 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2021-0098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 21 |b 13 |c 11 |h 1833-1843 | ||